DESCRIPTION: Atomoxetine selectively inhibits the reuptake of norepinephrine with little to no activity at the other neuronal reuptake pumps or receptor site.

INDICATION(S): Treatment of Attention Deficit Hyperactivity Disorder

REASONS FOR Step Therapy: ☒ Cost ☐ Potential for misuse ☐ Toxicity

CRITERIA for APPROVAL: The patient has had a 30 day trial and FAILURE of generic Amphetamine or Methylphenidate; EXCLUDING SAMPLES

REASON for DENIAL of BENEFIT: Patient does not meet above criteria

BENEFIT APPROVAL: Approval for a one year

References: